168 related articles for article (PubMed ID: 17880432)
1. Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data.
Richards M; Altisent C; Batorova A; Chambost H; Dolan G; de Moerloose P; Fraga M; Hermans C; Karafoulidou A; Klamroth R; Lassila R; Rothschild C
Haemophilia; 2007 Sep; 13(5):473-9. PubMed ID: 17880432
[TBL] [Abstract][Full Text] [Related]
2. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices.
Walsh CE; Valentino LA
Haemophilia; 2009 Sep; 15(5):1014-21. PubMed ID: 19493018
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis in adults with haemophilia.
Hay CR
Haemophilia; 2007 Sep; 13 Suppl 2():10-5. PubMed ID: 17685918
[TBL] [Abstract][Full Text] [Related]
4. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
[TBL] [Abstract][Full Text] [Related]
5. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs.
Tagliaferri A; Franchini M; Coppola A; Rivolta GF; Santoro C; Rossetti G; Feola G; Zanon E; Dragani A; Iannaccaro P; Radossi P; Mannucci PM
Haemophilia; 2008 Sep; 14(5):945-51. PubMed ID: 18540895
[TBL] [Abstract][Full Text] [Related]
6. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands.
van Dijk K; Fischer K; van der Bom JG; Scheibel E; Ingerslev J; van den Berg HM
Br J Haematol; 2005 Jul; 130(1):107-12. PubMed ID: 15982352
[TBL] [Abstract][Full Text] [Related]
7. Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan.
Liou WS; Tu TC; Cheng SN; Chou TY; Lee CF; Lin TK; Chung MI; Cham TM
Haemophilia; 2011 Jan; 17(1):45-54. PubMed ID: 20722742
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
Fischer K; Valentino L; Ljung R; Blanchette V
Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
[TBL] [Abstract][Full Text] [Related]
9. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
Taki M; Shirahata A
Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
[TBL] [Abstract][Full Text] [Related]
10. Practice patterns in haemophilia A therapy -- global progress towards optimal care.
Geraghty S; Dunkley T; Harrington C; Lindvall K; Maahs J; Sek J
Haemophilia; 2006 Jan; 12(1):75-81. PubMed ID: 16409179
[TBL] [Abstract][Full Text] [Related]
11. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life.
Khawaji M; Astermark J; Berntorp E
Eur J Haematol; 2012 Apr; 88(4):329-35. PubMed ID: 22221195
[TBL] [Abstract][Full Text] [Related]
12. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
Astermark J; Morado M; Rocino A; van den Berg HM; von Depka M; Gringeri A; Mantovani L; Garrido RP; Schiavoni M; Villar A; Windyga J;
Haemophilia; 2006 Jul; 12(4):363-71. PubMed ID: 16834735
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic use of factor VIII: an economic evaluation.
Bohn RL; Avorn J; Glynn RJ; Choodnovskiy I; Haschemeyer R; Aledort LM
Thromb Haemost; 1998 May; 79(5):932-7. PubMed ID: 9609224
[TBL] [Abstract][Full Text] [Related]
15. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
[TBL] [Abstract][Full Text] [Related]
16. Assessment of haemophilia treatment practice pattern in Japan.
Ono O; Suzuki Y; Yosikawa K; Wada I; Doi Y; Takano M; Wada Y; Fukushima K;
Haemophilia; 2009 Sep; 15(5):1032-8. PubMed ID: 19476508
[TBL] [Abstract][Full Text] [Related]
17. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors.
Ullman M; Hoots WK
Haemophilia; 2006 Dec; 12 Suppl 6():74-9; discussion 79-80. PubMed ID: 17123398
[TBL] [Abstract][Full Text] [Related]
18. Changing pattern of care of boys with haemophilia in western European centres.
Chambost H; Ljung R;
Haemophilia; 2005 Mar; 11(2):92-9. PubMed ID: 15810909
[TBL] [Abstract][Full Text] [Related]
19. Factor VIII half-life and intensity of treatment in hemophilic patients.
Vicente V
Haematologica; 2005 Apr; 90(4):437. PubMed ID: 15820932
[TBL] [Abstract][Full Text] [Related]
20. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A.
Richards M; Williams M; Chalmers E; Liesner R; Collins P; Vidler V; Hanley J;
Br J Haematol; 2010 May; 149(4):498-507. PubMed ID: 20230411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
